Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04562532 · ClinicalTrials.gov registry record · NA
Firehawk Rapamycin Target Eluting Coronary Stent North American Trial
A NA study of Coronary Artery Disease, sponsored by Shanghai MicroPort Medical (Group) Co..
- Active
- Registry status
- NA
- Development phase
- 1,720
- Enrollment target
- 20
- Study locations
NCT04562532: Active NA study of Coronary Artery Disease, sponsored by Shanghai MicroPort Medical (Group) Co..
NCT04562532 is a NA study of Coronary Artery Disease that is active but no longer recruiting, run by Shanghai MicroPort Medical (Group) Co.. The registered enrollment target is 1,720 participants, above the 1,279-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (34% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04562532, a NA study of Coronary Artery Disease, is active but no longer recruiting, sponsored by Shanghai MicroPort Medical (Group) Co..
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 1,720 participants
- Enrollment target
- 20
- Study locations
Study Summary
The aim of the TARGET-IV NA trial is to demonstrate the clinical non-inferiority of the Firehawk® rapamycin eluting stent system in comparison to currently approved 2nd generation DES for the treatment of subjects with ischemic heart disease (NSTEMI, recent STEMI (\>24 hours from initial presentation and in whom enzyme levels have peaked), unstable angina, and stable coronary disease), with atherosclerotic target lesion(s) in coronary arteries with visually estimated reference vessel diameters ≥2.25 mm and ≤4.0 mm.
Primary Outcome
Percentage of participants that had either Cardiac Death, Myocardial Infarction (not clearly attributable to a non-target vessel)or Target Lesion Revascularization (TLR, clinically indicated) after one year
Conditions Studied
Interventions
- DEVICE Microport Firehawk stent
- DEVICE 2nd generation DES (XIENCE family, Promus family, Resolute/Onyx family/Endeavor, and Orsiro stent)
Study Locations (20)
California
- UC San Diego School of Medicine - La Jolla
- Riverside Community Hospital - Riverside
- Sharp Memorial Hospital - San Diego
- Santa Barbara Cottage Hospital - Santa Barbara
Florida
- JFK Medical Center - Atlantis
- CCC Research - Countryside - Clearwater
- Clearwater Cardiovascular Consultants - Clearwater
- Memorial Hospital Jacksonville - Jacksonville
Massachusetts
- Massachusetts General Hospital - Boston
- Brigham and Womens Hospital - Boston
- Beth Israel Deaconess Medical Center, Inc. - Boston
Indiana
- Elkhart General Hospital - Elkhart
- St. Vincent Heart Center of Indiana - Indianapolis
Alabama
- Cardiology PC - Birmingham
Arizona
- Mercy Gilbert Medical Center - Gilbert
Connecticut
- Yale New Heaven Hospital - New Haven
Georgia
- Atlanta Veterans Affairs Medical Center - Decatur
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,720 participants |
| Start Date | 2021-02-17 |
| Est. Completion | 2027-06-30 |
| Phase | NA |
What the registry record for NCT04562532 still lists
NCT04562532 is an interventional study that assigns participants to a tested intervention. Its 1,720 participants enrollment target places it among the larger protocols in the corpus, above the 1,279-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (34% higher).
The record links to 1 condition, with Coronary Artery Disease appearing as the primary indexed condition, and to 2 interventions - of which Microport Firehawk stent is the first listed.
NCT04562532 names 20 study sites across 11 states, led by California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04562532 about?
NCT04562532 is a clinical study titled "Firehawk Rapamycin Target Eluting Coronary Stent North American Trial". The aim of the TARGET-IV NA trial is to demonstrate the clinical non-inferiority of the Firehawk® rapamycin eluting stent system in comparison to currently approved 2nd generation DES for the treatment of subjects with ischemic heart disease (NSTEMI, recent STEMI (\>24 hours from initial presentatio...
What is the current status of trial NCT04562532?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 1,720 participants. The study started on 2021-02-17. Estimated completion is 2027-06-30.
What conditions does trial NCT04562532 study?
This clinical trial studies the following conditions: Coronary Artery Disease.
What interventions are being tested in trial NCT04562532?
The interventions under investigation include: Microport Firehawk stent (DEVICE), 2nd generation DES (XIENCE family, Promus family, Resolute/Onyx family/Endeavor, and Orsiro stent) (DEVICE).
Who is sponsoring clinical trial NCT04562532?
This trial is sponsored by Shanghai MicroPort Medical (Group) Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04562532 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Artery Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04562532's enrollment target sits among peer trials
1,720 31st of 219 higher than 189 of 219 other Coronary Artery Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Coronary Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation
RECRUITING · NA
-
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
RECRUITING · NA
-
PET/CT* vs. Cardiac CT for Detecting Coronary Atherosclerotic Disease [*PET: Positron Emission Tomography; CT: Computed Tomography]
RECRUITING · NA
-
Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Change in Cardiovascular Health
RECRUITING · NA
-
Impact of Disclosing Coronary Artery Disease Polygenic Risk Score on Cardiovascular Health
RECRUITING · NA
-
Intravascular Lithotripsy With or Without Rotational Atherectomy for Coronary Calcified Nodule Treatment
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06898034 · 1,725 participants
Postpartum Ultrasound Evaluation to Assess Risk of Hemorrhage
- NCT04291612 · 1,715 participants
Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
- NCT05303636 · 1,710 participants · Phase 4
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women
- NCT06413420 · 1,731 participants
SUNOSI® (Solriamfetol) Pregnancy Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI